<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643643</url>
  </required_header>
  <id_info>
    <org_study_id>A4001007</org_study_id>
    <nct_id>NCT00643643</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus</brief_title>
  <official_title>A Randomised, Double Blind, Placebo-Controlled, Multicentre Study Of UK-427,857 25mg O.D. , 50mg B.I.D., 100mg B.I.D And 300mg B.I.D. In Asymptomatic HIV Infected Patients To Investigate Pharmacodynamics, Pharmacokinetics, Safety And Toleration.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the relationship between the pharmacokinetics and pharmacodynamics of
      UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">June 2003</completion_date>
  <primary_completion_date type="Actual">June 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in viral load</measure>
    <time_frame>Day 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of UK-427,857</measure>
    <time_frame>Days 1 and 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Receptor saturation</measure>
    <time_frame>Days 1, 5, 10, 11, 13, 15, 19, 40</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-lead electrocardiography</measure>
    <time_frame>Days 1-11 and Day 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course of viral load from baseline to follow-up</measure>
    <time_frame>Days 1-15 and Days 19, 22, 25, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rebound of viral load</measure>
    <time_frame>Days 1-15 and Days 19, 22, 25, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship of change in viral load (from baseline to day 11) versus average (Days 1-11) and trough (Day 10) plasma concentrations</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship of change in viral load (from baseline to day 11) versus mean receptor saturation (Day 10)</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relationship of change from baseline in viral load versus baseline virus susceptibility (IC 50 and IC 90)</measure>
    <time_frame>Days 1-11</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Days 1-40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory safety testing</measure>
    <time_frame>Days 1, 3, 7, 11, 15, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination</measure>
    <time_frame>Days 1, 11, 40</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supine and standing blood pressure and pulse rate</measure>
    <time_frame>Days 1-11 and Day 40</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>25 mg oral tablet once daily for 10 days</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>50 mg oral tablet twice daily for 10 days</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>100 mg oral tablet twice daily for 10 days</description>
    <arm_group_label>C</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Maraviroc (UK-427,857)</intervention_name>
    <description>300 mg oral tablet twice daily for 10 days</description>
    <arm_group_label>D</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo oral tablet twice daily for 10 days</description>
    <arm_group_label>E</arm_group_label>
    <other_name>Celsentri, Selzentry</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Inclusion criteria:

          -  Male with HIV or surgically sterilized female with HIV showing no symptoms of HIV

          -  Weight between 50 and 90kg and within the permitted range for their height

        Exclusion Criteria:

        Exclusion criteria:

          -  Subjects with a CD4 count less than 250cells/mm3 or HIV viral load of less than 5000
             copies/mL

          -  Subjects with acquired immune deficiency syndrome (AIDS) or a previous AIDS diagnosis

          -  Subjects whose HIV infection has been diagnosed less than 3 months prior to screening,
             or for who there is evidence of recent seroconversion

          -  Subjects who have taken anti-retroviral drugs in the eight weeks prior to the study
             screening visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koeln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001007&amp;StudyName=Pharmacokinetics%2C%20Pharmacodynamics%2C%20And%20Safety%20Of%20Maraviroc%20%28UK-427%2C857%29%20In%20Patients%20With%20Human%20Immunodeficiency%20Virus</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>November 9, 2010</last_update_submitted>
  <last_update_submitted_qc>November 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc</organization>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Treatment Na√Øve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

